drugset / Trial / NCT04633772
Use of Angiotensin-(1-7) in COVID-19
Phase 1/2
Completed
112 enrolled
Erasme University Hospital
Angitec · collabFederal University of Minas Gerais · collabFonds Erasme pour la Recherche Médicale · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The renin-angiotensin system (RAS) has a relevant role in COVID-19, as the virus will enter host's cells via the angiotensin-converting enzyme 2 (ACE2); RAS disequilibrium might also play a key role in the modulation of the inflammatory response that characterizes the lung involvement. Angiotensin-(1-7) is a peptide that could be altered in COVID-19 patient and its supplementation may potentially helpful in this setting.
Timeline
- Start
- 2020-08-05
- Primary completion
- 2021-11-01
- Completion
- 2021-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | talfirastide | Peptide | 10 ug/kg | Intravenous |